Stocks and Investing Stocks and Investing
Mon, November 13, 2017

Liav Abraham Maintained (TEVA) at Hold with Decreased Target to $13 on, Nov 13th, 2017


Published on 2024-10-26 00:54:48 - WOPRAI, Liav Abraham
  Print publication without navigation


Liav Abraham of Citigroup, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Hold with Decreased Target from $19 to $13 on, Nov 13th, 2017.

Liav has made no other calls on TEVA in the last 4 months.



There are 9 other peers that have a rating on TEVA. Out of the 9 peers that are also analyzing TEVA, 5 agree with Liav's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gregg Gilbert of "Deutsche Bank" Downgraded from Strong Buy to Hold on, Friday, November 3rd, 2017
  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $19 on, Friday, October 20th, 2017
  • Tyler Van Buren of "Cowen & Co." Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Derek Archila of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, August 3rd, 2017


These are the ratings of the 4 analyists that currently disagree with Liav


  • Vamil Divan of "Credit Suisse" Maintained at Sell with Decreased Target to $8 on, Monday, November 6th, 2017
  • David Risinger of "Morgan Stanley" Maintained at Sell with Decreased Target to $7 on, Friday, November 3rd, 2017
  • Tim Chiang of "BTIG" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, September 11th, 2017
  • Randall Stanicky of "RBC Capital" Downgraded from Buy to Sell on, Friday, August 4th, 2017
Contributing Sources